D3A.8 ICD-10-CM Code: Other benign neuroendocrine tumors
D3A.8 maps to CMS-HCC V28 22. A source-labeled RAF reference is available. Documentation must support MEAT. MEAT criteria · RAF Calculator · HCC coding software
HCC Buddy Code Card
Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.
FY 2026 Apr update / Neoplasms (C00-D49) / Benign neuroendocrine tumors (D3A)
D3A.8
Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidanceOther benign neuroendocrine tumors
A benign tumor arising from neuroendocrine cells in various body locations that does not fit into the standard carcinoid tumor categories.
Buddy Insight
This code covers benign neuroendocrine tumors that are not classified as carcinoid tumors, such as paragangliomas, pheochromocytomas with benign behavior, or other non-carcinoid neuroendocrine neoplasms.
CMS-HCC V28
MappedHCC 22
Code-level coefficient reference
CMS-HCC V24
HistoricalHistorical
Not used for CY2026 payment
ACA/HHS
N/A—
Not mapped
ESRD/PACE
N/A—
Not mapped
RXHCC
MappedHCC 22
Code-level coefficient reference
Code Book Path
Inclusion Terms
Official- Neuroendocrine tumor NOS
Excludes 2
Official- benign pancreatic islet cell tumors (D13.7)
Related Child Codes
Includes
OfficialICD-10-CM does not list Includes notes for D3A.8 in this effective period.
Excludes 1
OfficialICD-10-CM does not list Excludes 1 notes for D3A.8 in this effective period.
Code First
OfficialICD-10-CM does not list Code First sequencing instructions for D3A.8 in this effective period.
Use Additional
Official- code to identify any associated endocrine syndrome, such as:
- carcinoid syndrome (E34.00)
Code Also
Official- any associated multiple endocrine neoplasia [MEN] syndromes (E31.2-)
Buddy Documentation Tip
MEAT Support
Audit Caution
Common Mistakes
Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →
Is D3A.8 an HCC code?
Yes. D3A.8 (Other benign neuroendocrine tumors) maps to HCC 22, Bladder, Colorectal, and Other Cancers under the CMS-HCC V28 risk adjustment model, with a source-labeled community non-dual aged reference coefficient of 0.363. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes. It is billable for payment year 2026.
Coder answer: D3A.8 is billable and maps to V28 HCC 22, Bladder, Colorectal, and Other Cancers. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.
- Code
- D3A.8
- Description
- Other benign neuroendocrine tumors
- HCC (V28)
- HCC 22 — Bladder, Colorectal, and Other Cancers
- RAF reference coefficient
- 0.363
- Billable
- Yes
- Payment year
- 2026
HCC Category Mapping
These are source-labeled model coefficients, not member totals. A category may still be removed by hierarchy or model cleanup rules. Weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member context, hierarchy and cleanup rules, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains available for historical review.
Work D3A.8 in the Code Book — tabular path, V28 RAF reference, and MEAT checklist →
MEAT Criteria for D3A.8
For D3A.8 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed D3A.8 during that encounter, not just copy-forwarded from a problem list.
Coder workflow notes
Get the V28 mapping + MEAT cheat sheet
One printable reference: check representative V28 mappings and the documentation reminders your note needs. Free, no card.
Free PDF. No card. Unsubscribe anytime.
What This Code Means
D3A.8 is the ICD-10-CM diagnosis code for other benign neuroendocrine tumors. A benign tumor arising from neuroendocrine cells in various body locations that does not fit into the standard carcinoid tumor categories. D3A.8 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering benign neuroendocrine tumors (d3a).
Under the CMS-HCC V28 risk adjustment model, D3A.8 maps to Bladder, Colorectal, and Other Cancers (HCC 22) with a source-labeled community, non-dual, aged reference coefficient of 0.363. No V24 mapping is shown for D3A.8; use the applicable model and payment year when reviewing the V28 mapping. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition. Source-labeled code-level coefficients are references, not member totals. Actual contribution depends on complete member context, hierarchy and cleanup rules, interactions, and model year. HCC Buddy's RAF Calculator supports CMS-HCC V28 PY2026 and shows no score unless every required source and calculation check passes.
This is a catch-all code for benign neuroendocrine tumors not classified elsewhere; use only when more specific codes do not apply. Because D3A.8 maps to an HCC category, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) before the diagnosis is used for risk adjustment. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, source-labeled coefficient references, and MEAT documentation criteria for D3A.8 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •This is a catch-all code for benign neuroendocrine tumors not classified elsewhere; use only when more specific codes do not apply
- •Ensure pathology confirms neuroendocrine differentiation and benign behavior before assigning this code
Clinical Significance
This code covers benign neuroendocrine tumors that are not classified as carcinoid tumors, such as paragangliomas, pheochromocytomas with benign behavior, or other non-carcinoid neuroendocrine neoplasms. These tumors arise from specialized neuroendocrine cells and may produce various hormones depending on their cell of origin.
Documentation Requirements
- ✓Documentation should identify the specific type of neuroendocrine tumor and confirm benign behavior on pathology.
- ✓Immunohistochemistry confirming neuroendocrine lineage is essential.
- ✓Any hormonal activity, associated syndromes (such as Multiple Endocrine Neoplasia), and tumor location should be documented.
Commonly Confused Codes
- •D3A.090-D3A.098 codes are used for benign carcinoid tumors specifically and should be used when the neuroendocrine tumor is classified as a carcinoid type.
- •C7A.8 (other malignant neuroendocrine tumors) is the malignant counterpart.
- •E27.5 (adrenomedullary hyperfunction) may be relevant for functional tumors.